NFL Biosciences Files Patent Application to Protect Delivery of NFL-101

NFL Biosciences Files Patent Application to Protect Delivery of NFL-101

(AOF) – NFL Biosciences, a biopharmaceutical company developing botanical drugs for the treatment of dependence and addiction, announces that it has filed a new patent application aimed at protecting the administration of NFL-101 in combination with other smoking cessation treatments and in particular nicotine substitutes. The application was originally filed in the United States and will be extended internationally in accordance with NFL Biosciences’ intellectual property protection strategy.

NFL Biosciences intends to demonstrate the benefit of combining NFL-101 with other smoking cessation treatments and in particular with nicotine substitute treatments.

Before the launch of dedicated clinical studies, NFL Biosciences filed a patent application to protect the administration of NFL-101 before an attempt to quit concomitant with the initiation of another smoking cessation treatment and particularly by nicotine replacement therapy. .

Nicotine substitutes include transdermal patches (patches), tablets, chewing gum, inhalers and nicotine spray. They are used as a substitute for cigarettes after stopping or reducing cigarette smoking to alleviate withdrawal symptoms due to stopping or reducing nicotine intake.

The global market for smoking cessation drugs is estimated at nearly $6 billion (source: Coherent Market Insights); with an estimated growth of 6% over the next few years, it is nevertheless limited by a lack of more effective treatments without side effects.

Despite a modest efficacy at 6 months, around 15.7% (source: EAGLES), nicotine substitutes represent 80% of the market. They are the reference treatments because they have no significant side effects and because other drugs such as Champix/Chantix and Zyban, which have slightly higher efficiencies, are sometimes poorly tolerated.


The AOF information reproduced on is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial exploitation or not, creation of a hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address OPTION FINANCE SAS collects its data from the sources it considers the safest. However, subject to its gross negligence, OPTION FINANCES SAS and its contributors do not in any way guarantee the absence of error and defects, even hidden ones, nor the exhaustive nature or the lack of conformity for any use whatsoever of this data and of OPTION FINANCE SAS or one of its contributors, and cannot be held responsible for any delays or interruptions that may affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.

Leave a Comment

Your email address will not be published. Required fields are marked *